Digital memory tests flag subtle preclinical Alzheimer changes, especially with neocortical tau; scalable tools may boost future trial screening.
|Articles|December 17, 2011
Video: Determinants of Alzheimer Disease -- Is Our Destiny Genetic?
Author(s)Anton Porsteinsson, MD
In this video, Anton Porsteinsson, MD, discusses some of the causative factors of Alzheimer disease: genetics, environment, personality. He goes on to explain that although there are clear determinants for AD, there are preventive actions that can be taken to delay the onset of disability.
Advertisement
In this video, Anton Porsteinsson, MD, discusses some of the causative factors of Alzheimer disease: genetics, environment, personality. He goes on to explain that although there are clear determinants for AD, there are preventive actions that can be taken to delay the onset of disability.
Advertisement
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
FDA Shelves Fast-Track Drug Review Initiative
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
5